Pyxis Oncology Inc (PYXS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.61-3.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PYXS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 9.2% |
Growth built into the price is above our model estimate.
The price assumes 86.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
PYXS — earnings miss
Dated 2026-11-05
of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.
Why it matters: The FDA meeting is a key step before Pyxis can start its planned Phase 3 trial. A clear dose plan would support the mid-2027 start.
Supportive ifThe planned Q1 2027 FDA meeting ends with agreement on MICVO dose selection for the Phase 3 trial.
Worry ifThe FDA asks for more dose data or the dose meeting slips beyond Q1 2027.
Why it matters: Pyxis is loss-making, and trial costs continue as MICVO advances. The new cash figure will test whether funding still covers the planned work.
Worry ifOn November 2, Pyxis reports cash and states that funds cover operations into at least Q2 2027.
Less concerning ifThe company reports a shorter runway than Q2 2027 or says it needs new funding before then.
Why it matters: This update tests MICVO with pembrolizumab in first-line head and neck cancer. Clear tumor responses would support the combination plan.
Supportive ifThe Q4 2026 update shows confirmed tumor responses in first-line patients. It reports no new safety signal.
Worry ifThe update reports no confirmed responses, a new safety signal, or a delay past Q4 2026.
Why it matters: The Phase 1 study has not yet reached median overall survival. More follow-up will test whether early results last.
Watch forThe H1 2027 update says median overall survival is still unreached. The 12-month survival rate is 79% or higher.
Also watch forThe H1 2027 update says median overall survival has been reached, or the 12-month survival rate is below 79%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$430 on $10,000 · ±4.3% | How much price usually moves either way. |
| Bad day | $947 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,861 loss on $10,000 · 58.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The randomized trial is the next major test of MICVO in second-line and later disease. A start near mid-2027 would match the stated plan.
Supportive ifPyxis starts enrolling about 500 patients in the planned trial by mid-2027. The trial compares MICVO with the stated treatment choices.
Worry ifThe trial has not started by the end of 2027, or its planned size or comparison arms change.